TopPodcast.com
Menu
  • Home
  • Top Charts
  • Top Networks
  • Top Apps
  • Top Independents
  • Top Podfluencers
  • Top Picks
    • Top Business Podcasts
    • Top True Crime Podcasts
    • Top Finance Podcasts
    • Top Comedy Podcasts
    • Top Music Podcasts
    • Top Womens Podcasts
    • Top Kids Podcasts
    • Top Sports Podcasts
    • Top News Podcasts
    • Top Tech Podcasts
    • Top Crypto Podcasts
    • Top Entrepreneurial Podcasts
    • Top Fantasy Sports Podcasts
    • Top Political Podcasts
    • Top Science Podcasts
    • Top Self Help Podcasts
    • Top Sports Betting Podcasts
    • Top Stocks Podcasts
  • Podcast News
  • About Us
  • Podcast Advertising
  • Contact
Not in our directory?
Add Show Here
Podcast Equipment
Center

toppodcastlogoOur TOPPODCAST Picks

  • Comedy
  • Crypto
  • Sports
  • News
  • Politics
  • True Crime
  • Business
  • Finance

Follow Us

toppodcastlogoStay Connected

    View Top 200 Chart
    Back to Rankings Page
    Health & Fitness

    JAMA Oncology Author Interviews

    Interviews with authors of articles from JAMA Oncology. JAMA Oncology is the definitive journal for scientists, clinicians, and trainees in the field of oncology worldwide. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers. JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.

    Advertise
    • Apple Podcasts
    • Google Play
    • Spotify
    Latest Episodes:
    Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib Nov 21, 2024
    Show notes

    Interview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Content:

    • Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
    Anti–PD-L1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma Oct 24, 2024
    Show notes

    Interview with Maria E. Cabanillas, MD, author of Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Content:

    • Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma
    Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer Sep 05, 2024
    Show notes

    Interview with Eileen M. O'Reilly, MD, author of Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer. Hosted by Vivek Subbiah, MD. Related Content:

    • Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer
    Identification of Immune Checkpoint Inhibitor–Induced Diabetes Aug 29, 2024
    Show notes

    Interview with Michelle Rengarajan, MD, PhD, author of Identification of Immune Checkpoint Inhibitor–Induced Diabetes. Hosted by Vivek Subbiah, MD. Related Content:

    • Identification of Immune Checkpoint Inhibitor–Induced Diabetes
    Neoadjuvant Exercise Therapy in Prostate Cancer Jul 18, 2024
    Show notes

    Interview with Lee W. Jones, PhD, author of Neoadjuvant Exercise Therapy in Prostate Cancer: A Phase 1, Decentralized Nonrandomized Controlled Trial. Hosted by Vivek Subbiah, MD. Related Content:

    • Neoadjuvant Exercise Therapy in Prostate Cancer
    Endometrial Thickness as Diagnostic Triage for Endometrial Cancer in Black Individuals Jun 27, 2024
    Show notes

    Interview with Kemi M. Doll, MD, MSCR, author of Endometrial Thickness as Diagnostic Triage for Endometrial Cancer Among Black Individuals. Hosted by Vivek Subbiah, MD. Related Content:

    • Endometrial Thickness as Diagnostic Triage for Endometrial Cancer Among Black Individuals
    T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy Apr 18, 2024
    Show notes

    Interview with Roni Shouval, MD, PhD, author of T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy. Hosted by Vivek Subbiah, MD. Related Content:

    • T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy
    Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time Mar 21, 2024
    Show notes

    Interview with Tobias Janowitz, MD, PhD, and Karen Winkfield, MD, PhD, authors of Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time. Hosted by Vivek Subbiah, MD. Related Content:

    • Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time
    Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer Feb 29, 2024
    Show notes

    Interview with José P. Leone, MD, author of Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer. Hosted by Nora L. (Mary) Disis, MD. Related Content:

    • Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer
    Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US Jan 04, 2024
    Show notes

    Interview with Sajid A. Khan, MD, author of Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US. Hosted by Mary L. (Nora) Disis, MD. Related Content:

    • Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US
    Previous 1 2 3 4 13 Next

    Related Podcasts

    Fresh Air

    1

    Fresh Air Arts
    Twenty Thousand Hertz

    2

    Twenty Thousand Hertz Arts
    The Black Tapes

    3

    The Black Tapes Arts
    Snap Judgment

    4

    Snap Judgment Arts
    Here’s The Thing with Alec Baldwin

    5

    Here’s The Thing with Alec Baldwin Arts
    The NoSleep Podcast – Creative Reason Media Inc.

    6

    The NoSleep Podcast – Creative Reason Media Inc. Arts
    footer-logo

    Contact Us

    Toll Free: 844-670-7747

    Links

    • Home
    • Top Charts
    • Networks
    • Apps
    • Independents Podcasts
    • Podcast Advertising
    • Podcast News
    • Contact Us
    • About Us
    • Analytics & Insights

    Stay Connected

      Privacy, Terms of Use & Our Code of Ethics Protecting Content Creators Copyrights